News
03-22-2018, 04:24 AM
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.
More... (https://www.news-medical.net/news/20180322/Agendia-receives-CE-mark-for-MammaPrint-BluePrint-Breast-Cancer-Recurrence-and-Molecular-Subtyping-Kit.aspx)
More... (https://www.news-medical.net/news/20180322/Agendia-receives-CE-mark-for-MammaPrint-BluePrint-Breast-Cancer-Recurrence-and-Molecular-Subtyping-Kit.aspx)